GlassScriptPhysician profile
Robin Todd Hape
NPI 1639371818
$19,638.97
in general payments reported to CMS, 2019-2025
21 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $919 · 2021: $15K · 2022: $2,325 · 2023: $560 · 2024: $575 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.22 |
| Education | $133.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $16,878.78 | 2020-2024 | Da Vinci Surgical System |
| Endogastric Solutions, INC | $1,085.79 | 2019-2021 | |
| Hologic INC | $496.75 | 2021-2022 | |
| Hologic Sales and Service, LLC | $257.72 | 2023-2024 | Trident Specimen Radiography System, Localizer, Biozorb |
| Janssen Biotech, INC. | $227.74 | 2023-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $103.84 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2024-2025 | Imfinzi |
| Servier Pharmaceuticals LLC | $81.18 | 2023-2024 | |
| Lilly USA, LLC | $78.12 | 2023-2024 | Retevmo, Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $72.40 | 2025 | Libtayo |
| Adc Therapeutics America, INC. | $60.54 | 2024-2025 | |
| Seagen INC. | $41.16 | 2023 | Adcetris |
| Integra Lifesciences Corporation | $30.00 | 2019 | |
| Stemline Therapeutics INC. | $25.97 | 2025 | Orserdu |
| Tersera Therapeutics LLC | $20.08 | 2025 | Xermelo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $17.53 | 2023 | Phasix Mesh |
| Boston Scientific Corporation | $17.04 | 2021 | |
| Recordati_rare_diseases_inc. | $16.09 | 2023 | Sylvant |
| Exelixis INC. | $15.57 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $13.97 | 2023 | Imbruvica |
| Merit Medical Systems INC | $5.99 | 2024 | Savi Scout |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.